New imaging tracer lights up tumors in first human tests
NCT ID NCT06645808
First seen Jan 06, 2026 · Last updated Jun 15, 2026 · Updated 25 times
Summary
This early-phase study is testing a new radioactive imaging agent in 32 adults with various solid tumors. The goal is to see how the agent spreads through the body and whether it can highlight tumors on PET/CT scans. Participants receive a single injection of the agent and undergo imaging at several time points. The study focuses on safety and imaging results, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University Medical Center Groningen (UMCG)
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.